Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 5, 2013, Pages 2310-2318

  Buyck, Julien M ^a   Tulkens, Paul M ^a   Van Bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOSTASIS; COLONY FORMING UNIT; CONCENTRATION RESPONSE; ELECTRON MICROSCOPY; HUMAN; HUMAN CELL; INOCULATION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOCYTE; PH; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; BIOLOGICAL TRANSPORT; CELL LINE; CELL MEMBRANE PERMEABILITY; COLISTIN; COLONY COUNT, MICROBIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HUMANS; HYDROGEN-ION CONCENTRATION; KINETICS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MONOCYTES; PSEUDOMONAS AERUGINOSA; VACUOLES;

EID: 84876279043     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02609-12     Document Type: Article

References (39)

1. Fujitani S, Sun HY, Yu VL, Weingarten JA. 2011. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 139:909-919.
2. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F. 2007. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 13:560-578.
3. Kerem E, Corey M, Gold R, Levison H. 1990. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr. 116:714-719.
4. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, Collins J, Rock MJ, Splaingard ML. 2005. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293:581-588.
5. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 35:322-332.
6. Fleiszig SM, Zaidi TS, Fletcher EL, Preston MJ, Pier GB. 1994. Pseudomonas aeruginosa invades corneal epithelial cells during experimental infection. Infect. Immun. 62:3485-3493.
7. Chi E, Mehl T, Nunn D, Lory S. 1991. Interaction of Pseudomonas aeruginosa with A549 pneumocyte cells. Infect. Immun. 59:822-828.
8. Ha U, Jin S. 2001. Growth phase-dependent invasion of Pseudomonas aeruginosa and its survival within HeLa cells. Infect. Immun. 69:4398-4406.
9. Fleiszig SM, Zaidi TS, Pier GB. 1995. Pseudomonas aeruginosa invasion of and multiplication within corneal epithelial cells in vitro. Infect. Immun. 63:4072-4077.
10. Fleiszig SM, Evans DJ, Do N, Vallas V, Shin S, Mostov KE. 1997. Epithelial cell polarity affects susceptibility to Pseudomonas aeruginosa invasion and cytotoxicity. Infect. Immun. 65:2861-2867.
11. Evans D, Kuo T, Kwong M, Van R, Fleiszig S. 2002. Pseudomonas aeruginosa strains with lipopolysaccharide defects exhibit reduced intracellular viability after invasion of corneal epithelial cells. Exp. Eye Res. 75:635-643.
12. Hirakata Y, Yano H, Arai K, Endo S, Kanamori H, Aoyagi T, Hirotani A, Kitagawa M, Hatta M, Yamamoto N, Kunishima H, Kawakami K, Kaku M. 2010. Monolayer culture systems with respiratory epithelial cells for evaluation of bacterial invasiveness. Tohoku J. Exp. Med. 220:15-19.
13. Emam A, Carter WG, Lingwood C. 2010. Glycolipid-dependent, protease sensitive internalization of Pseudomonas aeruginosa into cultured human respiratory epithelial cells. Open Microbiol. J. 4:106-115.
14. Garcia-Medina R, Dunne WM, Singh PK, Brody SL. 2005. Pseudomonas aeruginosa acquires biofilm-like properties within airway epithelial cells. Infect. Immun. 73:8298-8305.
15. Del Porto P, Cifani N, Guarnieri S, Di Domenico EG, Mariggio MA, Spadaro F, Guglietta S, Anile M, Venuta F, Quattrucci S, Ascenzioni F. 2011. Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa. PLoS One 6:e19970. doi:10 .1371/journal.pone.0019970.
16. Schmiedl A, Kerber-Momot T, Munder A, Pabst R, Tschernig T. 2010. Bacterial distribution in lung parenchyma early after pulmonary infection with Pseudomonas aeruginosa. Cell Tissue Res. 342:67-73.
17. Kierbel A, Gassama-Diagne A, Mostov K, Engel JN. 2005. The phosphoinositol- 3-kinase-protein kinase B/Akt pathway is critical for Pseudomonas aeruginosa strain PAK internalization. Mol. Biol. Cell 16:2577-2585.
18. Sana TG, Hachani A, Bucior I, Soscia C, Garvis S, Termine E, Engel J, Filloux A, Bleves S. 2012. The second type VI secretion system of Pseudomonas aeruginosa strain PAO1 is regulated by quorum sensing and Fur and modulates internalization in epithelial cells. J. Biol. Chem. 287: 27095-27105.
19. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2006. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50:841-851.
20. Lemaire S, Kosowska-Shick K, Appelbaum PC, Verween G, Tulkens PM, Van Bambeke F. 2010. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob. Agents Chemother. 54:2549-2559.
21. Hartkoorn RC, Chandler B, Owen A, Ward SA, Bertel Squire S, Back DJ, Khoo SH. 2007. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis (Edinb) 87:248-255.
22. Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. 2003. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. North Am. 17:615-634.
23. Van Bambeke F, Barcia-Macay M, Lemaire S, Tulkens PM. 2006. Cellular pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives. Curr. Opin. Drug Discov. Devel. 9:218-230.
24. Lemaire S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2005. Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus. J. Antimicrob. Chemother. 55:897-904.
25. Lemaire S, Van Bambeke F, Tulkens PM. 2011. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila. Int. J. Antimicrob. Agents 38:52-59.
26. Vallet CM, Marquez B, Ngabirano E, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. 2011. Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/ pharmacodynamic model of uninfected and infected macrophages. Int. J. Antimicrob. Agents 38:249-256.
27. Sun HY, Fujitani S, Quintiliani R, Yu VL. 2011. Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy. Chest 139:1172-1185.
28. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. 22th informational supplement (MS100-S22). Clinical and Laboratory Standard Institute, Wayne, PA.
29. Ouadrhiri Y, Scorneaux B, Sibille Y, Tulkens PM. 1999. Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. Antimicrob. Agents Chemother. 43:1242-1251.
30. Rajan S, Cacalano G, Bryan R, Ratner AJ, Sontich CU, van Heerckeren A, Davis P, Prince A. 2000. Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells: analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factors. Am. J. Respir. Cell Mol. Biol. 23:304-312.
31. Hritonenko V, Evans DJ, Fleiszig SM. 2012. Translocon-independent intracellular replication by Pseudomonas aeruginosa requires the ADPribosylation domain of ExoS. Microbes Infect. 14:1366-1373.
32. Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, Tulkens PM, Van Bambeke F. 2012. Influence of the protein kinase C activator phorbol myristate acetate on the intracellular activity of antibiotics against heminand menadione-auxotrophic small-colony variant mutants of Staphylococcus aureus and their wild-type parental strain in human THP-1 cells. Antimicrob. Agents Chemother. 56:6166-6174.
33. Angus AA, Lee AA, Augustin DK, Lee EJ, Evans DJ, Fleiszig SM. 2008. Pseudomonas aeruginosa induces membrane blebs in epithelial cells, which are utilized as a niche for intracellular replication and motility. Infect. Immun. 76:1992-2001.
34. Lemaire S, Kosowska-Shick K, Appelbaum PC, Glupczynski Y, Van Bambeke F, Tulkens PM. 2011. Activity of moxifloxacin against intracellular community-acquired methicillin-resistant Staphylococcus aureus: comparison with clindamycin, linezolid and co-trimoxazole and attempt at defining an intracellular susceptibility breakpoint. J. Antimicrob. Chemother. 66:596-607.
35. Lemaire S, Tulkens PM, Van Bambeke F. 2011. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-grampositive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob. Agents Chemother. 55:649-658.
36. Carryn S, Van Bambeke F, Mingeot-Leclercq MP, Tulkens PM. 2002. Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations. Antimicrob. Agents Chemother. 46:2095-2103.
37. Amsden GW. 2009. Tables of antimicrobial agent pharmacology, p 705-764. In Mandell GL, Bennett JE, Dolin R (ed), Principles and practice of infectious diseases. Churchill Livingstone, Elsevier, Philadelphia, PA.
38. Bretonnière C, Jacqueline C, Caillon J, Guitton C, Le MV, Miegeville AF, Villers D, Potel G, Boutoille D. 2010. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem. J. Antimicrob. Chemother. 65:2423-2427.
39. Michalopoulos AS, Falagas ME. 2011. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann. Intensive Care 1:30. doi:10.1186/2110-5820-1-30.